Study register · detail
Clear benefit
GRADE
Low
184 citations
Samplen = 3.376 Pat.
Duration1988 to 1995
ControlControl persons without non-Hodgkin lymphoma
EndpointNon-Hodgkin lymphoma risk
Blindingn.a.
DesignFall-Kontroll-Studie (populationsbasiert)
Key finding
Lifetime cannabis use was associated with a reduced risk of non-Hodgkin lymphoma.
Summary
Population-based case-control study (n=1.281 NHL cases, n=2.095 controls) on non-Hodgkin lymphoma risk factors in the San Francisco Bay Area 1988–1995; in multivariate analysis, lifetime cannabis use was associated with a significantly reduced NHL risk (direction: negative risk; OR <1,0 in the final model).
P
PopulationWomen and heterosexual men in the San Francisco Bay Area, n=1.281 cases and 2.095 controls, population-based case-control study (1988–1995)
I
InterventionLifetime cannabis use history (among other factors in multivariate analysis)
C
ControlControl persons without non-Hodgkin lymphoma
O
OutcomeLifetime cannabis use was associated with a significantly reduced non-Hodgkin lymphoma risk (adjusted multivariate analysis; exact OR/CI not reported)
Confidence in the evidence
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
A population-based case-control study was conducted between 1988 and 1995 in the San Francisco Bay Area of California to determine risk factors for non-Hodgkin's lymphoma. Participants completed in-person interviews, and blood was drawn to test for viruses and lymphocyte subsets. This report includes data for 1,281 cases and 2,095 controls. In multivariate analyses, the factors associated with a decreased risk for non-Hodgkin's lymphoma were allergy to plants, bee and wasp stings, five or more vaccinations, drugs to lower blood cholesterol, nonsteroidal anti-inflammatory drugs, total number of sexual partners, and lifetime Cannabis use, whereas an increased risk was associated with cimetidine and other histamine H2-receptor antagonists, splenectomy, gonorrhea, and body mass index. Unique to sex-specific models was an increased risk for endocrine gland disorders among women and for polio among men. Median CD3, CD4, CD8, CD20, and lymphocyte counts for non-Hodgkin's lymphoma patients were significantly lower than those for controls. These results implicate environmental factors that may influence the early stages of lymphomagenesis by stimulating the immune system. Antigen-driven B cells that accumulate to form lymphoma may be suppressed by immunologic stresses such as exposure to an increased number of sexual partners and to certain medications. A history of allergies provides evidence for a persistent capacity for B-cell differentiation and therefore a decreased accumulation of B cells. The decreased risk for non-Hodgkin's lymphoma with use of nonsteroidal anti-inflammatory drugs and cholesterol-lowering drugs is consistent with a macrophage inflammatory role in B-cell proliferation.
The impediment to action advances action.